A Phase 3 interventional study of Finerenone (BAY94-8862) and Placebo in Chronic Kidney Disease, sponsored by Bayer. Completed at 978 sites in 48 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-24.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing finerenone in Renal Insufficiency, Chronic — 14 open to participants now, 16 under way, 4 of them phase 3. finerenone · Renal Insufficiency, Chronic.
Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, this one has the largest enrollment, is the only one that started in 2015, is one of 6 in phase 3, and was the 1st registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →14 of the 25 studies testing finerenone in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:
Peter Rossing · Sites in Denmark, Germany, Spain and 1 more country
Ages 18–75
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
University of Aarhus · Sites in Denmark
Ages 18+
The George Institute · Sites in Australia, India, New Zealand and 2 more countries
Ages 18+
Bayer · Sites in United States, Argentina, Australia and 29 more countries
Ages 1–18
By country, each count listing its studies:
finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,734 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 100 across the 25 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 25 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
49 studies in Renal Insufficiency, Chronic by Bayer: 4 open now, 8 under way, 2 of them phase 3. Of 39 finished, 4 (10%) have results posted.
Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one has the largest enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2015, is one of 9 in phase 3, and was the 8th registered.
Bayer’s Renal Insufficiency, Chronic studies by the year they started, since 2009.
6 of the studies testing finerenone in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07235891Alexandria UniversityRetinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease | 2026-12-20 |
| NCT07026539University of AarhusEffect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes. | 2026-12-31 |
| NCT07849348Peking University People's HospitalStudy on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria | 2027-02 |
| NCT07155694Washington D.C. Veterans Affairs Medical CenterRole of Finerenone in African American Veterans With Diabetic Kidney Disease | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, from their registry updates:
Among Bayer’s 49 in Renal Insufficiency, Chronic:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) ≥40% from baseline over at least 4 weeks, or renal death.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of chronic kidney disease (CKD) with at least one of the following criteria at run-in and screening visits:
Prior treatment with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy
Drug: Finerenone (BAY94-8862)
Participants received matching placebo once daily in addition to standard of care therapy
Drug: Placebo
Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to \< 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study; once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death
Count of participants and time from randomization to the first occurrence of the primary renal composite outcome, onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.
Time frame: From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months
The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, or Hospitalization for Heart Failure
Count of participants and time from randomization to the first occurrence of the key secondary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.
Time frame: From randomization up until the first occurrence of the key secondary CV composite endpoint, or censoring at the end of the study, with an average of 32 months
All-cause Mortality
Count of participants and time from randomization until death due to any cause were evaluated. Number of participants with outcome death is reported as descriptive result and hazard ratio is reported as statistical analysis. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table.
Time frame: From randomization up until death due to any cause, or censoring at the end of the study visit, with an average of 32 months
All-cause Hospitalization
Count of participants and time from randomization to the first occurrence of a hospitalization event were evaluated. Number of participants with the event is reported as descriptive result and hazard ratio is reported as statistical analysis.
Time frame: From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average of 32 months
Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline to Month 4
First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change.
Time frame: From baseline up until Month 4
The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death
Count of participants and time from randomization to the first occurrence of the secondary renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.
Time frame: From randomization up until the first occurrence of the composite primary endpoint, or censoring at the end of the study, with an average of 32 months
Study was conducted at multiple centers in 48 countries/regions between 17-SEP-2015 (first participant first visit) and 14-APR-2020 (last participant last visit).
| Milestone | Finerenone | Placebo |
|---|---|---|
| Started | 2866 | 2868 |
| Included in fas | 2833 | 2841 |
| Treated | 2827 | 2831 |
| Completed | 2824 | 2832 |
| Not completed | 42 | 36 |
| Withdrew: Lost to follow-up | 5 | 3 |
| Withdrew: Withdrawal by subject | 4 | 6 |
| Withdrew: Gcp violations | 33 | 27 |
Count of participants and time from randomization to the first occurrence of the primary renal composite outcome, onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.
| Participants | Finerenone | Placebo |
|---|---|---|
| The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death | 504 | 600 |
Count of participants and time from randomization to the first occurrence of the key secondary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.
| Participants | Finerenone | Placebo |
|---|---|---|
| The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, or Hospitalization for Heart Failure | 367 | 420 |
Count of participants and time from randomization until death due to any cause were evaluated. Number of participants with outcome death is reported as descriptive result and hazard ratio is reported as statistical analysis. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table.
| Participants | Finerenone | Placebo |
|---|---|---|
| All-cause Mortality | 219 | 244 |
Count of participants and time from randomization to the first occurrence of a hospitalization event were evaluated. Number of participants with the event is reported as descriptive result and hazard ratio is reported as statistical analysis.
| Participants | Finerenone | Placebo |
|---|---|---|
| All-cause Hospitalization | 1263 | 1321 |
First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change.
| Ratio | Finerenone | Placebo |
|---|---|---|
| Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline to Month 4 | 0.655 (0.637 to 0.673) | 0.952 (0.927 to 0.979) |
Count of participants and time from randomization to the first occurrence of the secondary renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis.
| Participants | Finerenone | Placebo |
|---|---|---|
| The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death | 252 | 326 |
Collected over After the first dose of study drug up to 3 days after any temporary or permanent interruption of study drug, with an average treatment duration of 27 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Finerenone | 222/2,833 (7.8%) | 902/2,827 (31.9%) | 1,602/2,827 (56.7%) |
| Placebo | 250/2,841 (8.8%) | 971/2,831 (34.3%) | 1,584/2,831 (56%) |
| Event | Finerenone | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 70/2827 | 103/2831 |
| Acute kidney injuryRenal and urinary disorders | 56/2827 | 51/2831 |
| HyperkalaemiaMetabolism and nutrition disorders | 42/2827 | 12/2831 |
| HypoglycaemiaMetabolism and nutrition disorders | 21/2827 | 31/2831 |
| CellulitisInfections and infestations | 26/2827 | 22/2831 |
| Urinary tract infectionInfections and infestations | 21/2827 | 23/2831 |
| HyperglycaemiaMetabolism and nutrition disorders | 17/2827 | 23/2831 |
| HypertensionVascular disorders | 15/2827 | 23/2831 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 14/2827 | 22/2831 |
| SyncopeNervous system disorders | 12/2827 | 22/2831 |
| Event | Finerenone | Placebo |
|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 422/2827 | 212/2831 |
| Oedema peripheralGeneral disorders | 183/2827 | 303/2831 |
| HypertensionVascular disorders | 200/2827 | 262/2831 |
| NasopharyngitisInfections and infestations | 241/2827 | 250/2831 |
| AnaemiaBlood and lymphatic system disorders | 201/2827 | 177/2831 |
| DiarrhoeaGastrointestinal disorders | 183/2827 | 188/2831 |
| Upper respiratory tract infectionInfections and infestations | 181/2827 | 185/2831 |
| Urinary tract infectionInfections and infestations | 168/2827 | 185/2831 |
| Glomerular filtration rate decreasedInvestigations | 177/2827 | 130/2831 |
| Back painMusculoskeletal and connective tissue disorders | 175/2827 | 170/2831 |
Full analysis set (FAS): the FAS comprised all randomized participants (except those with critical GCP violations)
| Age, Continuous(Years) | Finerenone | Placebo | Total |
|---|---|---|---|
| Mean | 65.44 ± 8.94 | 65.67 ± 9.16 | 65.56 ± 9.05 |
| Sex: Female, Male(Participants) | Finerenone | Placebo | Total |
|---|---|---|---|
| Female | 880 | 811 | 1691 |
| Male | 1953 | 2030 | 3983 |
| Ethnicity (NIH/OMB)(Participants) | Finerenone | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 447 | 431 | 878 |
| Not Hispanic or Latino | 2376 | 2397 | 4773 |
| Unknown or Not Reported | 10 | 13 | 23 |
| Race (NIH/OMB)(Participants) | Finerenone | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 78 | 76 | 154 |
| Asian | 717 | 723 | 1440 |
| Native Hawaiian or Other Pacific Islander | 11 | 7 | 18 |
| Black or African American | 140 | 124 | 264 |
| White | 1777 | 1815 | 3592 |
| More than one race | 101 | 86 | 187 |
| Unknown or Not Reported | 9 | 10 | 19 |
| Urinary albumin-to-creatinine ratio (UACR)(milligram/gram (mg/g)) | Finerenone | Placebo | Total |
|---|---|---|---|
| Median | 832.72 (441.00 to 1628.14) | 867.01 (453.11 to 1644.58) | 851.87 (446.24 to 1634.22) |
| Estimated glomerular filtration rate (eGFR)(mL/min/1.73m^2) | Finerenone | Placebo | Total |
|---|---|---|---|
| Mean | 44.36 ± 12.54 | 44.32 ± 12.57 | 44.34 ± 12.56 |
Showing the first 100 of 978 sites across 48 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2015 to primary completion in Apr 2020, 54 months.
Results were first posted in Jul 2021, 1 year 3 months after primary completion.
Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 54 months is above that.
Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Finerenone
Renal Insufficiency, Chronic →